Quetiapine Addition in Obsessive-Compulsive Disorder: Is Treatment Outcome Affected by Type and Dose of Serotonin Reuptake Inhibitors?

Biological Psychiatry

Volumn 61, Issue 3, 2007, Pages 412-414

  Denys, Damiaan ^a   Fineberg, Naomi ^b   Carey, Paul D ^c   Stein, Dan J ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Obsessive compulsive disorder; quetiapine; serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADD ON THERAPY; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RATING SCALE; SAMPLE SIZE; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33846234757     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.12.014     Document Type: Article

References (9)

1. Carey P.D., Vythilingum B., Seedat S., Muller J.E., Van Ameringen M., and Stein D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebo-controlled study. BMC Psychiatry 5 (2005) 5
2. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 29 (2006) 553-584 xi
3. Denys D., de Geus F., van Megen H.J., and Westenberg H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65 (2004) 1040-1048
4. Fineberg N.A., Sivakumaran T., Roberts A., and Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: A randomized controlled treatment study. Int Clin Psychopharmacol 20 (2005) 223-226
5. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46 (1989) 1006-1011
6. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazziti D., Rasmussen S.A., et al. Refractory obsessive-compulsive disorder: State-of-the-art treatment. J Clin Psychiatry 63 suppl 6 (2002) 20-29
7. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 161 (2004) 826-835
8. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 suppl 20 (1998) 22-33
9. Tatsumi M., Groshan K., Blakely R.D., and Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340 (1997) 249-258